The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis

Matthew D Campbell, Daniel J West, Lauren L O'Mahoney, Sam Pearson, Noppadol Kietsiriroje, Mel Holmes, Ramzi A Ajjan, Matthew D Campbell, Daniel J West, Lauren L O'Mahoney, Sam Pearson, Noppadol Kietsiriroje, Mel Holmes, Ramzi A Ajjan

Abstract

Purpose: The exact contribution of daily glucose exposure to HbA1c in people with type 1 diabetes (T1D) remains controversial. We examined the contribution of pre- and postprandial glycaemia, nocturnal and early-morning glycaemia, and glycaemic variability to HbA1c levels in T1D. In this analysis, we used clinical data, namely age, BMI and HbA1c, as well as glycaemic metrics (24-h glycaemia, postprandial, nocturnal, early-morning glycaemia, wake-up glucose, and glycaemic variability) obtained over a four-week period of continuous glucose monitoring (CGM) wear in thirty-two males with T1D.

Methods: The trapezoid method was used estimate the incremental area under the glucose curve (iAUC) for 24-h, postprandial (3-h period following breakfast, lunch, and dinner, respectively), nocturnal (between 24:00-04:00 AM), and early-morning (2-h period 2-h prior to wake-up) glycaemia. Linear regression analysis was employed whereby CGM-derived glycaemic metrics were explanatory variables and HbA1c was the outcome.

Results: Thirty-two T1D males (mean ± SD: age 29 ± 4 years; HbA1c 7.3 ± 0.9% [56 ± 13 mmol/mol]; BMI 25.80 ± 5.01 kg/m2) were included in this analysis. In linear models adjusted for age and BMI, HbA1c was associated with 24-h mean glucose (r 2 = 0.735, p < 0.001), SD (r 2 = 0.643, p = 0.039), and dinner iAUC (r 2 = 0.711, p = 0.001). CGM-derived metrics and non-glycaemic factors explained 77% of the variance in HbA1c, in which postprandial glucose accounted for 32% of the variance explained. The single greatest contributor to HbA1c was dinner iAUC resulting in 0.6%-point (~7 mmol/mol) increase in HbA1c per SD increase in dinner iAUC.

Conclusions: Using comprehensive CGM profiling, we show that postprandial glucose, specifically evening-time postprandial glucose, is the single largest contributing factor to HbA1c in T1D.

Trial registration number: NCT02204839 (July 30th 2014); NCT02595658 (November 3rd 2015).

Keywords: CGM; Glucose variability; HbA1c; Postprandial glucose; Type 1 diabetes.

Conflict of interest statement

Conflicts of interest/ Competing interestsNo conflicts of interest or competing interests relevant to this article are reported.

© The Author(s) 2022.

Figures

Fig. 1
Fig. 1
A-J Participant CGM-derived metrics. Breakfast, lunch, and dinner iAUC was calculated for 3-h after each meal. Early morning iAUC was calculated for a 2-h period prior to wake-up time. Nocturnal iAUC was calculated between 02:00–04:00 for all participants
Fig. 2
Fig. 2
Pairwise scatter plots of the interrelationships between CGM-derived metrics with mean and 95%CI
Fig. 3
Fig. 3
A-J Pairwise scatter plots of the interrelationships between CGM-derived metrics vs. HbA1c, with mean and 95%CI
Fig. 4
Fig. 4
A-C (A) Mean (95%CI) difference in HbA1c (%) by 1-SD difference in CGM-derived glycaemic metrics. Estimated differences are unadjusted (grey) and adjusted (black) for age and BMI. (B) Proportion of variance explained in HbA1c by postprandial factors (black bar; breakfast iAUC, lunch iAUC, dinner iAUC), preprandial factors (grey bar; nocturnal iAUC, early-morning iAUC, wake-up glucose), glycaemic variability (hashed bar; SD, CV%), and non-glycaemic factors (white bar; age, BMI). (C) Sensitivity analysis of proportion of variance explained in HbA1c by postprandial factors (black bar; dinner iAUC), preprandial factors (grey bar; nocturnal iAUC), glycaemic variability (hashed bar; SD), and non-glycaemic factors (white bar; age, BMI)

References

    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187.
    1. DCCT Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75:894–903. doi: 10.1016/s0002-9149(99)80683-3.
    1. DCCT Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:17–23. doi: 10.2337/dc13-2251.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil H, Andrew W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/nejm199309303291401.
    1. Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32:1901–1903. doi: 10.2337/dc09-0109.
    1. DCCT Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39:1378–1383. doi: 10.2337/dc15-2399.
    1. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31:714–719. doi: 10.2337/dc07-2124.
    1. Adler A, Erqou S, Lima T, Robinson A. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. Diabetologia. 2010;53:840–849. doi: 10.1007/s00125-009-1638-7.
    1. Jeffcoate S. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med. 2004;21:657–665. doi: 10.1046/j.1464-5491.2003.01065.x.
    1. Kuenen JC, Borg R, Kuik DJ, Zheng H, Schoenfeld D, Diamant M, et al. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients? Diabetes Care. 2011;34:1843–1847. doi: 10.2337/dc10-2217.
    1. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. Journal of Diabetes. 2009;1:9–17. doi: 10.1111/j.1753-0407.2009.00009.x.
    1. Dubowitz N, Xue W, Long Q, Ownby J, Olson D, Barb D, et al. Aging is associated with increased HbA1c levels, independently of glucose levels and insulin resistance, and also with decreased HbA1c diagnostic specificity. Diabet Med. 2014;31:927–935. doi: 10.1111/dme.12459.
    1. Campbell MD, Walker M, Ajjan RA, Birch KM, Gonzalez JT, West DJ. An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: a randomised controlled trial. Diabetes and Vascular Disease Research. 2017;14:336–344. doi: 10.1177/1479164117698918.
    1. Campbell MD, Walker M, Bracken RM, Turner D, Stevenson EJ, Gonzalez JT, et al. Insulin therapy and dietary adjustments to normalize glycemia and prevent nocturnal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. BMJ Open Diabetes Research and Care. 2015;3:e000085. doi: 10.1136/bmjdrc-2015-000085.
    1. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–1640. doi: 10.2337/dc17-1600.
    1. Færch K, Alssema M, Mela DJ, Borg R, Vistisen D. Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA 1c in individuals with and without diabetes. Nutrition & Diabetes. 2018;8:1–9. doi: 10.1038/s41387-018-0047-8.
    1. Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Archives of Public Health. 2015;73:43. doi: 10.1186/s13690-015-0088-6.
    1. Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev. 2004;20:S9–S12. doi: 10.1002/dmrr.517.
    1. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34:S184–SS90. doi: 10.2337/dc11-s216.
    1. Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12:42–46. doi: 10.4158/EP.12.S1.42.
    1. Monnier L, Colette C. Postprandial and basal hyperglycaemia in type 2 diabetes: contributions to overall glucose exposure and diabetic complications. Diabetes Metab. 2015;41:6S9–6S15. doi: 10.1016/S1262-3636(16)30003-9.
    1. Haddadinezhad S, Ghazaleh N. Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics. Int J Diabetes Develop Countries. 2010;30:8–10. doi: 10.4103/0973-3930.60002.
    1. Hillman N, Herranz L, Grande C, Villaroel A, Pallardo LF. Is HbA1c influenced more strongly by preprandial or postprandial glycemia in type 1 diabetes? Diabetes Care. 2002;25:1100–1101. doi: 10.2337/diacare.25.6.1100.
    1. Gupta S, Puppalwar PV, Chalak A. Correlation of fasting and post meal plasma glucose level to increased HbA1c levels in type-2 diabetes mellitus. Int J Adv Med. 2014;1:127–131.
    1. DECODE/EDEG. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397.
    1. Meigs JB, Nathan DM, D’Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care. 2002;25:1845–1850. doi: 10.2337/diacare.25.10.1845.
    1. Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? J Diabetes Complicat. 2016;30:374–385. doi: 10.1016/j.jdiacomp.2015.09.019.
    1. IDF. Guideline for management of postmeal glucose: Brussels, Belgium: International Diabetes Federation (IDF); 2017 [24/05/2020]. Available from: .
    1. DCCT/EDIC. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–693.
    1. Lind M, Svensson A-M, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–1982. doi: 10.1056/NEJMoa1408214.
    1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–885. doi: 10.2337/diacare.26.3.881.
    1. Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173–177. doi: 10.1089/dia.2009.0112.
    1. Gingras V, Taleb N, Roy-Fleming A, Legault L, Rabasa-Lhoret R. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. Diabetes Obes Metab. 2018;20:245–256. doi: 10.1111/dom.13052.
    1. Campbell MD, Walker M, Ajjan RA, Birch KM, Gonzalez JT, West DJ. An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: a randomised controlled trial. Diab Vasc Dis Res. 2017;14:336–344. doi: 10.1177/1479164117698918.
    1. Campbell MD, Walker M, Ajjan RA, Birch KM, Gonzalez JT, West DJ. An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors. Diabetes Care. 2015;38:S9–S10.
    1. NICE. Type 1 diabetes in adults: diagnosis and management; 1.4 Dietary Management 2019 [14/08/2019]. Available from: .
    1. Conn JW, Newburgh L. The glycemic response to isoglucogenic quantities of protein and carbohydrate. J Clin Invest. 1936;15:665–671. doi: 10.1172/JCI100818.
    1. Jenkins D, Wolever T, Taylor RH, Barker H, Fielden H, Baldwin JM, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362–366. doi: 10.1093/ajcn/34.3.362.
    1. Dodd H, Williams S, Brown R, Venn B. Calculating meal glycemic index by using measured and published food values compared with directly measured meal glycemic index. Am J Clin Nutr. 2011;94:992–996. doi: 10.3945/ajcn.111.012138.
    1. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015;38:1008–1015. doi: 10.2337/dc15-0100.
    1. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–1094. doi: 10.1016/j.cell.2015.11.001.
    1. Dingena C, Marsh A, Ajjan RA, Campbell MD. Postprandial glucose variability in people with type 1 diabetes is individual and impacted by physiological and clinical parameters. Diabetes. 2020;61.
    1. Tsujino D, Nishimura R, Onda Y, Seo C, Ando K, Morimoto A, et al. The relationship between HbA1c values and the occurrence of hypoglycemia as assessed by continuous glucose monitoring in patients with type 1 diabetes. Diabetol Metabol Syndrome. 2016;8:53. doi: 10.1186/s13098-016-0167-z.
    1. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia. 1991;34:21–28. doi: 10.1007/BF00404020.
    1. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40:832–838. doi: 10.2337/dc16-1769.
    1. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008;112:4284–4291. doi: 10.1182/blood-2008-04-154112.
    1. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, et al. Evidence for Interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57:2445–2452. doi: 10.2337/db07-1820.
    1. Xu Y, Bergenstal RM, Dunn TC, Ajjan RA. Addressing shortfalls of laboratory HbA(1c) using a model that incorporates red cell lifespan. Elife. 2021;10:e69456. doi: 10.7554/eLife.69456.
    1. Xu Y, Dunn TC, Ajjan RA. A kinetic model for glucose levels and hemoglobin A1c provides a novel tool for individualized diabetes management. J Diabetes Sci Technol. 2021;15:294–302. doi: 10.1177/1932296819897613.
    1. Xu Y, Grimsmann J, Karges B, Hofer S, Danne T, Holl R, et al. Personal glycation factors and calculated HbA1c for diabetes management: real-world data from the DPV registry. Diabetes Technol Ther. 2021;23. 10.1089/dia.2020.0553.
    1. Xu Y, Hirota Y, Ajjan RA, Yamamoto A, Matsuoka A, Ogawa W, et al. Accurate prediction of HbA1c by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell lifespan and glucose uptake. Diabetes Vasc Dis Res. 2021;18:14791641211013734. doi: 10.1177/14791641211013734.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi